Breast Cancer Clinical Trial
Official title:
Exercise Diet and Sex Hormones in Postmenopausal Women (NEW)
RATIONALE: A low-calorie diet and/or exercise program may help lower an overweight or obese
postmenopausal woman's risk of developing breast cancer. It is not yet known whether a
low-calorie diet and/or exercise program are more effective than no diet or exercise program
in lowering an overweight or obese postmenopausal woman's risk of developing breast cancer.
PURPOSE: This randomized clinical trial is studying the effect of a low-calorie diet and/or
exercise program on risk factors for developing breast cancer compared with no diet or
exercise program in overweight or obese postmenopausal women.
OBJECTIVES:
Primary
- Compare the effects of a 1-year exercise intervention, reduced-calorie diet
intervention, or a combined exercise and reduced-calorie diet intervention vs no
intervention on serum estrone concentrations in overweight or obese postmenopausal
women.
Secondary
- Compare the effects of these interventions on serum levels of estradiol and free
estradiol in these participants.
- Compare the effects of these interventions on serum levels of testosterone and free
testosterone in these participants.
- Compare the effects of these interventions on serum levels of sex hormone binding
globulin in these participants.
- Compare the effects of these interventions on serum levels of insulin in these
participants.
- Compare the effects of these interventions on serum levels of glucose in these
participants.
- Compare the effects of these interventions on serum levels of c-peptide in these
participants.
- Compare the effects of these interventions on serum levels of insulin-like growth
factor I (IGF-1) in these participants.
- Compare the effects of these interventions on serum levels of insulin-like growth
factor binding-protein-3 (IGFBP-3) in these participants.
- Compare the effects of these interventions on serum levels of c-reactive protein (CRP)
in these participants.
- Compare the effects of these interventions on serum levels of serum amyloid protein A
(SAA) in these participants.
- Compare the effects of these interventions on serum levels of interleukin-6 (IL-6) in
these participants.
- Compare the effects of these interventions on serum levels of adiponectin in these
participants.
- Compare the effects of these interventions on serum levels of leptin in these
participants.
- Compare the effects of these interventions on serum levels of ghrelin in these
participants.
- Compare the effects of these interventions on serum levels of Vitamin D in these
participants.
- Compare the effects of these interventions on mammographic density in these
participants.
- Compare the effects of these interventions on anthropometrics and body composition
(i.e., weight, body mass index, total and percentage body fat, and waist and hip
circumferences) in these participants.
- Compare the effects of these interventions on quality of life in these participants.
- Compare the effects of these interventions on numbers of leukocytes and neutrophiles in
these participants.
- Compare the effects of these interventions on VO2max in these participants.
OUTLINE: This is a randomized study. Participants are stratified according to body mass
index (< 30 vs ≥ 30). Participants are randomized to 1 of 4 intervention arms.
- Arm I (exercise program): Participants exercise 3 days per week under the supervision
of a physiologist and 2 days per week independently at home, for a total of 5 exercise
sessions (at least 45 minutes of moderate-intensity exercise per session) weekly over
12 months.
- Arm II (reduced-calorie diet): Participants meet with a nutritionist individually and
in small groups. Participants receive general information about diet and behavior
strategies such as self-monitoring, goal-setting, stimulus-control, problem-solving,
and relapse-prevention training. Participants learn to set a calorie goal and a fat
gram goal and how to achieve the goal calorie reduction. Meetings are held weekly
during the first 6 months of the diet program but taper off over the course of the
study.
- Arm III (exercise program and reduced-calorie diet): Participants meet with a
physiologist and a nutritionist, as in arms I and II, and exercise and diet
accordingly.
- Arm IV (control: delayed diet and exercise): Participants receive study materials on
healthy diet and exercise at the end of the 12-month study period. In addition,
participants are offered 2 months of group exercise training with a study physiologist
and 4 group meetings with a nutritionist to learn about weight loss techniques and
behavioral principles for achieving weight loss.
All participants undergo testing at baseline and periodically during study. Participants
undergo blood collection for evaluation of serum levels of sex and metabolic hormones (e.g.,
estrone, estradiol, testosterone, free testosterone, and sex hormone binding globulin,
radioimmunoassay and other immunoassays. Participants also undergo anthropometrics and body
composition measurements and mammographic density assessment.
Participants complete questionnaires at baseline and at 6 and 12 months for assessment of
diet and exercise. Quality of life (QOL) is measured at baseline and at 6 and 12 months
using the Medical Outcomes Study 36-Item Short Form and the Impact of Weight on QOL
questionnaire. Information on health habits, medical history, family history of breast
cancer, and reproductive and menstrual history is also collected.
FINAL ACCRUAL: A total of 439 participants (118 in the caloric restriction arm, and 117 in
both the CR+Exercise, and exercise only arm; and 87 in control arm) were accrued for this
study.
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |